Economic Impact

Estimated economic benefits of the T2Bacteria Panel

Bacterial bloodstream infections are very common, and the pathogens covered by the T2Bacteria® Panel, which is currently available for Research Use Only (RUO) in the U.S. and CE Marked in the EU, are among the most deadly and costly to treat. A wide variety of studies have documented that getting the right treatment to patients with bacterial bloodstream infections within the first 24 hours of presentation can yield cost savings in the range of $22,000 to $38,000 per patient.1-8 With its unmatched combination of speed and sensitivity, the T2Bacteria Panel is projected to help hospitals achieve savings similar to those already demonstrated by the T2Candida® Panel

In addition, negative T2Bacteria results will provide significant economic and clinical value once commercially available. A negative result may enable physicians to discontinue the use of expensive empiric therapies or substitute with effective and less expensive therapies.

Estimated length of stay & cost reductions with appropriate Rx in 1st 24 hours1


 

Patients presenting in hospitals, including emergency departments (ED)

  • Hospital inpatients are reimbursed under DRG codes and all cost savings associated with T2MR testing accrue to the hospital
  • 50-60% of sepsis episodes are diagnosed in the ED9
  • Most common pathogenic isolates in ED: Staphylococcus aureus (34.1%) and Escherichia coli (22.8%) accounted for 56.9%10
  • Existing CDPT codes provide over $290 of reimbursement per T2Bacteria test11
  • Hospital CLABSI rates can be improved by an accurate detection for inpatients or in the ED by properly identifying patients with infections that might otherwise be classified as Hospital Acquired Infections
 
……………………………………….
1. Estimated economic and clinical impact based on the following studies for specified bacterial species, assuming ultimate regulatory approval, not actual historical results. This page contains T2's estimates, which constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. See "Forward-Looking Statements" and the factors discussed under Item 1A. "Risk Factors" in the company's most recent Annual Report on Form 10-K for the prior fiscal year, filed with the U.S. Securities and Exchange Commission, or SEC, and other filings the company makes with the SEC from time to time.
2. Beekmann, S. E., Diekema, D. J., Chapin, K. C., & Doern, G. V. (2003). Effects of rapid detection of bloodstream infections on length of hospitalization and hospital charges. Journal of clinical microbiology, 41(7), 3119-3125.
3. Micek, S. T., Lloyd, A. E., Ritchie, D. J., Reichley, R. M., Fraser, V. J., & Kollef, M. H. (2005). Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrobial agents and chemotherapy, 49(4), 1306-1311.
4. Sunenshine, R. H., Wright, M., Maragakis, L. L., Harris, A. D., Song, X., Hebden, J….Srinivasan, A. (2007). Multidrug-resistant Acinetobacter Infection Mortality Rate and Length of Hospitalization. Emerging Infectious Diseases, 13(1), 97.
5. Kim, B. N., Woo, J. H., Kim, M. N., Ryu, J., & Kim, Y. S. (2002). Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. Journal of Hospital Infection, 52(2), 99-106.4.
6. Abramson, M. A., & Sexton, D. J. (1999). Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs?. Infection Control & Hospital Epidemiology, 20(06), 408-411.
7. Stosor, V., Peterson, L. R., Postelnick, M., & Noskin, G. A. (1998). Enterococcus faecium bacteremia: does vancomycin resistance make a difference?. Archives of Internal Medicine, 158(5), 522-527.2. Abramson, et al. Infection Control & Hospital Epidemiology 20.06 (1999): 408-411.
8. Golan, Y., Wolf, M. P., Pauker, S. G., Wong, J. B., & Hadley, S. (2005). Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis. Annals of internal medicine, 143(12), 857-869.
9. Garnacho-Montero, J., Gutiérrez-Pizarraya, A., Escoresca-Ortega, A., Fernández-Delgado, E., & López-Sánchez, J. M. (2015). Adequate antibiotic therapy prior to ICU admission in patients with severe sepsis and septic shock reduces hospital mortality. Critical care, 19(1), 302.
10. Tsalik, E. L., Jones, D., Nicholson, B., Waring, L., Liesenfeld, O., Park, L. P., … & Cairns, C. B. (2010). Multiplex PCR to diagnose bloodstream infections in patients admitted from the emergency department with sepsis. Journal of clinical microbiology, 48(1), 26-33.
11. This information is provided for illustrative purposes and cannot cover all situations or all third-party payers’ rules or policies, nor can use of the information guarantee coverage or payment. CPT is a registered trademark of the American Medical Association (AMA). All rights reserved.